We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $1.94B
1-Year Est. Return 374.45%
This Fund
S&P 500
This Quarter Est. Return
+18.58%
1 Year Est. Return
+374.45%
3 Year Est. Return
+1,279.72%
5 Year Est. Return
+2,528.28%
10 Year Est. Return
–
AUM
$733M
AUM Growth
-$135M
Cap. Flow
-$230M
Cap. Flow %
-31.36%
Top 10 Hldgs %
42.15%
Holding
113
New
16
Increased
22
Reduced
29
Closed
27

Top Buys

Rank Stock Value
1
ORKA
Oruka Therapeutics
ORKA
+$12M
2
NUVL
Nuvalent
NUVL
+$11.4M
3
ALKS icon
Alkermes
ALKS
+$9.33M
4
ARWR icon
Arrowhead Research
ARWR
+$6.71M
5
VRDN icon
Viridian Therapeutics
VRDN
+$6.13M

Top Sells

Rank Stock Value
1
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$20.4M
2
ONC
BeOne Medicines Ltd
ONC
+$13.5M
3
CLDX icon
Celldex Therapeutics
CLDX
+$13.4M
4
MORF
Morphic Holding, Inc. Common Stock
MORF
+$8.54M
5
APGE icon
Apogee Therapeutics
APGE
+$8.25M

Sector Composition

Rank Sector Weight
1 Healthcare 81.54%
2 Financials 0.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVTX icon
76
Avalo Therapeutics
AVTX
$976M
$426K 0.06%
45,000
– –
VYGR icon
77
Voyager Therapeutics
VYGR
$187M
$303K 0.04%
+51,727
New +$376K
MTVA
78
MetaVia Inc
MTVA
$7.64M
$283K 0.04%
8,111
– –
GNLX icon
79
Genelux
GNLX
$130M
$237K 0.03%
100,000
– –
WHWK
80
Whitehawk Therapeutics
WHWK
$183M
$96.9K 0.01%
+47,019
New +$76K
PMN icon
81
ProMIS Neurosciences
PMN
$109M
$38.3K 0.01%
1,226
-9,412
-88% -$351K
RCKTW icon
82
Rocket Pharmaceuticals Warrant
RCKTW
$320K
$5.25K ﹤0.01%
75,000
– –
ADCT icon
83
ADC Therapeutics
ADCT
$146M
– –
-474,744
Closed -$1.5M
ALXO icon
84
CALL
ALX Oncology
ALXO
$273M
– –
-100,000
Closed -$603K
BDTX icon
85
Black Diamond Therapeutics
BDTX
$101M
– –
-650,000
Closed -$3.03M
DYN icon
86
Dyne Therapeutics
DYN
$4.04B
– –
-100,000
Closed -$3.53M
ELEV
87
DELISTED
Elevation Oncology
ELEV
– –
-1,468,825
Closed -$3.97M
FULC icon
88
CALL
Fulcrum Therapeutics
FULC
$248M
– –
-250,000
Closed -$1.55M
HLVX
89
DELISTED
HilleVax
HLVX
– –
-265,859
Closed -$3.84M
INSM icon
90
PUT
Insmed
INSM
$23.2B
– –
-8,700
Closed -$583K
IOVA icon
91
Iovance Biotherapeutics
IOVA
$2.23B
– –
-100
Closed -$802
IOVA icon
92
PUT
Iovance Biotherapeutics
IOVA
$2.23B
– –
-150,000
Closed -$1.2M
MRSN
93
DELISTED
Mersana Therapeutics
MRSN
– –
-30,680
Closed -$1.54M
OLMA icon
94
Olema Pharmaceuticals
OLMA
$1.02B
– –
-275,000
Closed -$2.98M
PASG icon
95
Passage Bio
PASG
$15.9M
– –
-13,213
Closed -$210K
PCVX icon
96
CALL
Vaxcyte
PCVX
$7.89B
– –
-15,000
Closed -$1.13M
RAPT
97
DELISTED
RAPT Therapeutics
RAPT
– –
-9,375
Closed -$229K
RAPT
98
PUT
DELISTED
RAPT Therapeutics
RAPT
– –
-68,125
Closed -$1.66M
SANA icon
99
PUT
Sana Biotechnology
SANA
$885M
– –
-521,000
Closed -$2.84M
SPY icon
100
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$778B
– –
-350,000
Closed -$190M
1 2 3
4
5

Similar funds

FM
Foster & Motley Cincinnati, Ohio $1.94B AUM 21.65% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $1.94B AUM 20.3% 1-Year Est. Return
HCL
Heard Capital LLC Chicago, Illinois $1.93B AUM 21.66% 1-Year Est. Return
OCM
Osterweis Capital Management San Francisco, California $1.94B AUM 20.77% 1-Year Est. Return
HC
Hamilton Capital Columbus, Ohio $1.93B AUM
FFH
Fairfax Financial Holdings Toronto, Ontario, Canada $1.94B AUM 27.76% 1-Year Est. Return
BC
Blackhill Capital Morristown, New Jersey $1.94B AUM 18.09% 1-Year Est. Return
WPC
Waters Parkerson & Co New Orleans, Louisiana $1.95B AUM 15.9% 1-Year Est. Return

Affinity Asset Advisors's Q3 2024 Portfolio in Review

As of Q3 2024, Affinity Asset Advisors held 113 positions worth $733M, down 16% from $868M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Affinity Asset Advisors withdrew a net $230M in Q3 2024, closing 27 positions and reducing 29 holdings. Its most notable exit was Cerevel Therapeutics Holdings, Inc. Common Stock, an estimated $20.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 65% a quarter earlier, followed by Financials.

Against the trend, Affinity Asset Advisors opened a new position in Arvinas worth $5.54M.

  • Affinity Asset Advisors's largest Q3 2024 buy was Arvinas: 225,000 shares worth $5.54M.
  • Affinity Asset Advisors added most to Oruka Therapeutics in Q3 2024, an estimated $12M increase.
  • Affinity Asset Advisors's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $13.5M.
  • Affinity Asset Advisors fully exited Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2024, selling an estimated $20.4M.
  • Affinity Asset Advisors's ten largest holdings make up 42% of its $733M portfolio in Q3 2024.
  • Affinity Asset Advisors opened 16 new positions and closed 27 in Q3 2024.
  • Affinity Asset Advisors's portfolio value fell 16% quarter-over-quarter to $733M.

Based on Affinity Asset Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.